GT Biopharma
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
505 Montgomery St Fl 10, San Francisco, ...Phone Number
(415) 919-4040Website
www.gtbiopharma.comRevenue
-Stock Symbol
GTBPIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About GT Biopharma
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on the company's proprietary TriKE® NK cell engager platform. The company's TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient's immune system's natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology.Explore more
GT Biopharma Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GT Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
GT Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if GT Biopharma had a recent Job posting/layoffs
Product Launch: Get notified when GT Biopharma launches new products
Earning: See what the market has to say on GT Biopharma recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once GT Biopharma has new funding data
Check out if GT Biopharma is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at GT Biopharma
Check if GT Biopharma has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at GT Biopharma
Find 3 more new buyers
Compare Similar Companies to GT Biopharma
Compare insights from companies similar to GT Biopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
GT Biopharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
GT Biopharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about GT Biopharma.
GT Biopharma financials insights
Gather financial insights about GT Biopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$500K
2016
Private Equity
$4.5M
2018
Debt
$7.1M
GT Biopharma Tech Stack
A closer look at the technologies used by GT Biopharma
See more technologies
Most Recent Scoops
Project
Product Development, Legal Affairs, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Initial Public Offering (IPO)
Earnings
Clinical Operations, Operations
Earnings
Financial Planning, Clinical Operations, Finance, Financial Strategy, Operations
Earnings
GT Biopharma News & Media
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing developmental costsEXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout
GT Biopharma Inc. (NASDAQ:GTBP) on Monday said its recently implemented artificial intelligence-based technologies are improving drug discovery productivity and pipeline development efficiency, with the company expecting additional development candidates to advance into pre-IND development in 2027. AI Tools Drive Discovery And Engineering Efficiencies The clinical-stage immuno-oncology company, which develops therapies based on its proprietary natural killer cell engager TriKE platform, said theGT Biopharma Reports First Quarter 2026 Financial Results
Phase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with additional updates anticipated in 2H 2026GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
GTB-5550 is now the 3rd TriKE® to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalation phase
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GT Biopharma
Sign Up For FreeTo access detailed company insights
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on the company's proprietary TriKE® NK cell engager platform. The company's TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient's immune system's nat... Read More
